Five Prime Therapeutics (FPRX) Sees Windfall on Anti-CSF1R Collaboration Agreement (BMY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program
October 15, 2015 4:05 AM EDTSOUTH SAN FRANCISCO, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will host a conference call and live audio webcast today, October 15 at 8:30 a.m. (ET)/5:30 a.m. (PT) to discuss the new worldwide license and... More
Five Prime Therapeutics to Host Conference Call on Worldwide License and Collaboration Agreement With Bristol-Myers Squibb for CSF1R Antibody Program
October 15, 2015 4:05 AM EDTSOUTH SAN FRANCISCO, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ: FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will host a conference call and live audio webcast today, October 15 at 8:30 a.m. (ET)/5:30 a.m. (PT) to discuss the new worldwide license and... More
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015 4:00 AM EDTStrategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients
Five Prime to receive up to $1.74 billion for FPA008, inclusive of $350 million upfront and potential development and regulatory milestone payments; additional double-digit royalties on future sales and option to co-promote in the U.S.
Five Prime to continue development of FPA008 in pigmented villonodular synovitis (PVNS) and in potential combinations with its own immuno-oncology... More
Bristol-Myers Squibb Enters Into Exclusive Worldwide License and Collaboration Agreement With Five Prime Therapeutics for Colony Stimulating Factor 1 Receptor (CSF1R) Antibody Program
October 15, 2015 4:00 AM EDTStrategic immuno-oncology collaboration focused on development of CSF1R antibody (FPA008) in combination with Opdivo (nivolumab) and other therapies with the goal of bringing new treatment options to patients
Five Prime to receive up to $1.74 billion for FPA008, inclusive of $350 million upfront and potential development and regulatory milestone payments; additional double-digit royalties on future sales and option to co-promote in the U.S.
Five Prime to continue development of FPA008 in pigmented villonodular synovitis (PVNS) and in potential combinations with its own immuno-oncology... More
